HK1102366A1 - Factor ixa for the treatment of bleeding disorders - Google Patents

Factor ixa for the treatment of bleeding disorders

Info

Publication number
HK1102366A1
HK1102366A1 HK07109313.4A HK07109313A HK1102366A1 HK 1102366 A1 HK1102366 A1 HK 1102366A1 HK 07109313 A HK07109313 A HK 07109313A HK 1102366 A1 HK1102366 A1 HK 1102366A1
Authority
HK
Hong Kong
Prior art keywords
factor ixa
bleeding disorders
treatment
factor
subject
Prior art date
Application number
HK07109313.4A
Other languages
English (en)
Inventor
Shane Donovan
Donald A Baker
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of HK1102366A1 publication Critical patent/HK1102366A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK07109313.4A 2004-03-19 2007-08-27 Factor ixa for the treatment of bleeding disorders HK1102366A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55472604P 2004-03-19 2004-03-19
PCT/US2005/006527 WO2005094873A1 (en) 2004-03-19 2005-02-28 Factor ixa for the treatment of bleeding disorders

Publications (1)

Publication Number Publication Date
HK1102366A1 true HK1102366A1 (en) 2007-11-16

Family

ID=34961495

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07109313.4A HK1102366A1 (en) 2004-03-19 2007-08-27 Factor ixa for the treatment of bleeding disorders

Country Status (10)

Country Link
US (2) US7425539B2 (xx)
EP (1) EP1755652B1 (xx)
JP (2) JP5037331B2 (xx)
AT (1) ATE489105T1 (xx)
AU (1) AU2005228945B2 (xx)
CA (1) CA2557061C (xx)
DE (1) DE602005024955D1 (xx)
ES (1) ES2357132T3 (xx)
HK (1) HK1102366A1 (xx)
WO (1) WO2005094873A1 (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005024955D1 (de) * 2004-03-19 2011-01-05 Baxter Healthcare Sa Faktor ixa zur behandlung von blutungsstörungen
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
SG11201406671RA (en) 2012-04-19 2014-11-27 Opko Biolog Ltd Long-acting oxyntomodulin variants and methods of producing same
MY172997A (en) 2012-11-20 2019-12-18 Opko Biologics Ltd Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
FR3032621A1 (fr) 2015-02-13 2016-08-19 Lab Francais Du Fractionnement Colle biologique et son utilisation comme medicament
AU2016248817A1 (en) * 2015-04-17 2017-08-17 F. Hoffmann-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
IL301728A (en) 2015-06-19 2023-05-01 Opko Biologics Ltd Long-term coagulation factors and methods for their preparation
CA3009458A1 (en) * 2016-01-07 2017-07-13 Eio Biomedical Ltd Methods, compositions and kits for reducing tissue adhesions
BR112019000610A2 (pt) 2016-07-11 2019-07-02 Opko Biologics Ltd fator vii de coagulação de longa ação e métodos de produção do mesmo
CN107758662B (zh) * 2017-10-10 2019-08-20 中国石油大学(华东) 一种磷酸法活性炭活化时间的确定方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560475A (en) 1969-06-19 1971-02-02 Baxter Laboratories Inc Prothrombin complex prepared by precipitation with polyethylene glycol
US4357321A (en) * 1980-01-28 1982-11-02 Baxter Travenol Laboratories, Inc. Method and composition for treating clotting factor inhibitors
US4286056A (en) 1980-01-28 1981-08-25 Baxter Travenol Laboratories, Inc. Method for making therapeutic enzyme compositions
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4770999A (en) 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
ES2045167T5 (es) 1987-10-23 1996-07-01 Centre Regional De Transfusion Preparacion de concentrado de factor ix humano de elevada pureza y de otras proteinas plasmaticas.
US5583107A (en) * 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US20040072757A1 (en) 1990-09-04 2004-04-15 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
DE19506633A1 (de) 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
BR0008405B1 (pt) 1999-02-22 2014-04-22 Baxter Int Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
EP1048736A1 (en) 1999-04-27 2000-11-02 Aventis Behring Gesellschaft mit beschränkter Haftung DNA-construct for the tissue specific expression of a blood coagulation factor
US6441144B1 (en) * 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
US6624289B1 (en) * 1999-06-16 2003-09-23 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
JP2003518494A (ja) * 1999-12-29 2003-06-10 グラクソ グループ リミテッド アネキシンおよび軟骨ホメオスタシスのモジュレーターに関係する方法と組成物
DE60115613T2 (de) 2000-03-22 2006-08-24 Octagene Gmbh Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
US7125841B2 (en) 2000-11-14 2006-10-24 The University Of Texas Systems Mutant human factor IX with an increased resistance to inhibition by heparin
US20030203845A1 (en) 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US7015193B2 (en) 2001-04-20 2006-03-21 University Of Vermont Compositions and methods to control bleeding
US7977460B2 (en) * 2003-05-19 2011-07-12 National Institute For Biological Standards And Control Compositions comprising coagulation factors IXA and VIII for the treatment of haemophilia A or B
DE602005024955D1 (de) 2004-03-19 2011-01-05 Baxter Healthcare Sa Faktor ixa zur behandlung von blutungsstörungen

Also Published As

Publication number Publication date
WO2005094873A1 (en) 2005-10-13
CA2557061A1 (en) 2005-10-13
US20050209149A1 (en) 2005-09-22
CA2557061C (en) 2013-08-20
JP2007529518A (ja) 2007-10-25
ATE489105T1 (de) 2010-12-15
JP2012126743A (ja) 2012-07-05
US7767647B2 (en) 2010-08-03
EP1755652A1 (en) 2007-02-28
DE602005024955D1 (de) 2011-01-05
AU2005228945A1 (en) 2005-10-13
US20090069543A1 (en) 2009-03-12
US7425539B2 (en) 2008-09-16
AU2005228945B2 (en) 2010-09-30
ES2357132T3 (es) 2011-04-19
EP1755652B1 (en) 2010-11-24
JP5037331B2 (ja) 2012-09-26

Similar Documents

Publication Publication Date Title
HK1102366A1 (en) Factor ixa for the treatment of bleeding disorders
EA200401525A1 (ru) Способы лечения гепатита (варианты )
RS91004A (xx) Postupci za lečenje ileusa
UA88645C2 (ru) Гетероарильные соединения как бета-миметики для лечения заболеваний дыхательных путей
TWI319708B (en) Methods and compositions for altering cell fuction
UA92355C2 (xx) 2,4-ДІАМІНОПІРИМІДИНИ ЯК ІНГІБІТОРИ AURORA$urn:schemas-microsoft-com:office:smarttags2,4-ДИАМИНОПИРИМИДИНЫ КАК ИНГИБИТОРЫ AURORA
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
WO2006042249A3 (en) Methods and compositions for treating migraine pain
TW200612892A (en) Novel compounds
WO2004069190A3 (en) Combination therapy for treating protein deficiency disorders
TW200510416A (en) P38 inhibitors and methods of use thereof
GB2442915B (en) Perylenequinone derivatives and uses thereof
TW200505416A (en) Bi-aryl compound having immunosuppressive activity
TW200736213A (en) Dicarboxylic acid derivatives and their use
MY144616A (en) Substituted dihydroquinazolines
TW200700071A (en) Novel use
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
UA85676C2 (xx) Карбонільні сполуки[карбонильные соединения
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
TW200635920A (en) Pyrazinedicarboxamides and their use
MXPA05005915A (es) Soluciones de albumina humana terapeutica con baja actividad del activador de precalicreina (pka) y procedimiento de obtencion de las mismas.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140228